ERBB2 and cancer: It has been shown that site-specifically modified Her2-binding IgG antibodies based on E.coli cell-free systems have been coupled to the anti-cancer agent monomethyl auristatin F, delivering the antibody-drug conjugate to the antigen (Zimmerman et al., 2014).